Literature DB >> 19761840

Bacterially expressed recombinant envelope protein domain III of Japanese encephalitis virus (rJEV-DIII) elicits Th1 type of immune response in BALB/c mice.

Shailendra Kumar Verma1, Subodh Kumar, Nimesh Gupta, Satish Vedi, Shailja Misra Bhattacharya, P V Lakshmana Rao.   

Abstract

Japanese encephalitis is a major cause of encephalitis in Asia. Cases occur largely in rural areas of the South and East Asian region resulting in significant morbidity and mortality. Multiple vaccines exist to control Japanese encephalitis, but all suffer from problems. Envelope protein domain III of Japanese encephalitis virus is involved in binding to host receptors and it contains specific epitopes that elicit virus-neutralizing antibodies. Earlier, the protective efficacy of domain III has been evaluated in mice by some researchers, but these studies are lacking in explanation of humoral and cellular immune responses. We have earlier reported cloning, expression, purification and in vitro refolding of Japanese encephalitis virus envelope protein domain III (rJEV-DIII). Ninety percent JEV is neutralized when the serum against refolded rJEV-DIII is used at a dilution of 1:80. In the present study, we have evaluated the immunomodulatory potential of refolded rJEV-DIII protein in BALB/c mice with Freunds complete/incomplete adjuvants. Mice were tested for humoral immune response by ELISA. Cell-mediated immune response was tested by lymphocyte proliferation assay and cytokine profiling. The rJEV-DIII generated high IgG antibody and its isotypes (IgG2a and IgG3) and induced significant expression of INF-gamma and IL-2 cytokines. The rJEV-DIII induced significant lymphoproliferation of splenocytes. In conclusion rJEV-DIII induced Th1 type of immune response which plays an important role in protection for intracellular pathogens.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19761840     DOI: 10.1016/j.vaccine.2009.09.006

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Evaluation of extracellular subviral particles of dengue virus type 2 and Japanese encephalitis virus produced by Spodoptera frugiperda cells for use as vaccine and diagnostic antigens.

Authors:  Miwa Kuwahara; Eiji Konishi
Journal:  Clin Vaccine Immunol       Date:  2010-07-28

2.  Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.

Authors:  Matthew D Dunn; Shannan L Rossi; Donald M Carter; Matthew R Vogt; Erin Mehlhop; Michael S Diamond; Ted M Ross
Journal:  Virol J       Date:  2010-05-12       Impact factor: 4.099

3.  HSP70 domain II of Mycobacterium tuberculosis modulates immune response and protective potential of F1 and LcrV antigens of Yersinia pestis in a mouse model.

Authors:  Lalit Batra; Shailendra K Verma; Durgesh P Nagar; Nandita Saxena; Prachi Pathak; Satish C Pant; Urmil Tuteja
Journal:  PLoS Negl Trop Dis       Date:  2014-12-04

Review 4.  Japanese encephalitis: the virus and vaccines.

Authors:  Sang-Im Yun; Young-Min Lee
Journal:  Hum Vaccin Immunother       Date:  2013-10-25       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.